Introduction
============

Exercise is recommended for patients with various diseases including cancer ([@b1-ol-0-0-11345],[@b2-ol-0-0-11345]). Walking as well as resistance training has been reported to improve physical function and skeletal muscle mass in patients with cancer ([@b3-ol-0-0-11345],[@b4-ol-0-0-11345]). In accordance with the American College of Sports Medicine guidelines, exercise training is a key recommendation to maintain activity even in cancer patients ([@b5-ol-0-0-11345]). Cancer rehabilitation (CR), a new multidisciplinary intervention for cancer patients, consists of nutritional and physical therapy. CR improves fatigue, pain, physical function, and quality of life in patients with cancer ([@b6-ol-0-0-11345]).

Sarcopenia is defined as loss of skeletal muscle mass and function. Sarcopenia frequently occurs in patients with chronic liver disease (CLD) regardless of its etiology ([@b7-ol-0-0-11345],[@b8-ol-0-0-11345]). Sarcopenia in patients with CLD is associated with a decline in their quality of life and physical activity ([@b9-ol-0-0-11345]). Sarcopenia is also significantly associated with hepatic fibrosis ([@b10-ol-0-0-11345]). Moreover, sarcopenia is an independent prognostic factor for hepatocellular carcinoma (HCC) ([@b11-ol-0-0-11345]). Taken together, it is important to pay attention to sarcopenia in patients with CLD.

In patients with cirrhosis and esophageal varices, moderate-intensity exercise increases portal pressure and may, therefore, increase the risk of variceal bleeding ([@b12-ol-0-0-11345]). In addition, moderate-intensity exercise stimulates the renal vasoconstrictor system, markedly impairing the renal function in patients with cirrhosis and ascites ([@b13-ol-0-0-11345]). In this way, exercise may exacerbate the general condition of patients of cirrhosis with complications such as esophageal varices and ascites. However, Hiraoka *et al* ([@b14-ol-0-0-11345]) showed that branched-chain amino acid (BCAA) supplementation and low-intensity exercise are effective for improving muscle volume and strength in patients with CLD. In addition, Locklear *et al* ([@b15-ol-0-0-11345]) demonstrated that, even in patients with end-stage liver disease, exercise has potential benefits in terms of endurance and functional outcome measures without adverse effects. We also previously reported that CR improved not only physical ability but also muscle mass without worsening liver function during hospitalization for cancer treatment in patients with CLD and advanced HCC ([@b16-ol-0-0-11345],[@b17-ol-0-0-11345]).

Thus, CR has beneficial effects on sarcopenia in patients with CLD and HCC; however, the effects of CR on prognosis remain unclear in patients with CLD and advanced HCC. This study aimed to investigate the effects of CR on the prognosis of patients with CLD and advanced HCC.

Patients and methods
====================

### Study design

CR for in-hospital patients with cancer is an approved health care service covered by health insurance from the Ministry of Health, Labour and Welfare in Japan. Therefore, intentionally using a non-exercise control group is contrary to medical ethics. Thus, we performed a prospective cohort study to evaluate effects of CR on skeletal muscle mass during hospitalization for patients with HCC and CLD who underwent TACE.

### Ethics

The study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki, as reflected in the prior approval given by the institutional review board of Kurume University (approval no. 15072). Informed consent was obtained from an opt-out approach, and personal information was protected during data collection.

### Subjects

A total of 152 consecutive patients with HCC and CLD from February 2013 to October 2016 participated in this study. Inclusion criteria were hospitalized patients with HCC and CLD who ([@b1-ol-0-0-11345]) were 20 years of age or older, ([@b2-ol-0-0-11345]) had a performance status of grade 0 to 2 as defined by the Eastern Cooperative Oncology Group ([@b18-ol-0-0-11345]), and ([@b3-ol-0-0-11345]) had undergone treatment with TACE. Exclusion criteria were patients with ([@b1-ol-0-0-11345]) risk of HCC rupture, ([@b2-ol-0-0-11345]) history or presence of grade 2--4 hepatic encephalopathy according to the West Haven Criteria ([@b19-ol-0-0-11345]), ([@b3-ol-0-0-11345]) risk of esophageal or gastric varices rupture, ([@b4-ol-0-0-11345]) heart failure, or ([@b5-ol-0-0-11345]) respiratory failure. The exclusion criteria were assessed upon study enrollment. All patients underwent upper gastrointestinal endoscopy by gastroenterologists every 6 to 12 months, and the risk of esophageal or gastric varices rupture was assessed according to the 2015 evidence-based clinical practice guidelines for liver cirrhosis from the Japanese Society of Gastroenterology ([@b20-ol-0-0-11345]). The definition of heart failure was based on guidelines from the American College of Cardiology Foundation/American Heart Association Task Force and Heart Failure Society of America ([@b21-ol-0-0-11345],[@b22-ol-0-0-11345]). The definition of respiratory failure was based on guidelines from the European Respiratory Society/American Thoracic Society ([@b23-ol-0-0-11345],[@b24-ol-0-0-11345]). Outpatient doctors and nurses recommended exercise to all patients. Patients who agreed to exercise were classified into the CR group (n=85), and those who did not agree to exercise were classified into the control group (n=67). We classified enrolled patients into the High SMI or Low SMI group according to the JSH criteria for sarcopenia ([@b7-ol-0-0-11345]), and the High VFA or Low VFA group as previously described ([@b25-ol-0-0-11345]). We also divided the patients into the High or Low LDH group and the High total protein group or Low total protein group based on the reference values of serum LDH and total protein levels, respectively.

### Exercise regimen

To maintain physical ability and prevent sarcopenia, patients in the CR group were treated with exercise, instructed by physical therapists certified in the rehabilitation of cancer patients. The rehabilitation was started on the day following TACE unless the patient had a fever of 38°C or greater as previously described ([@b16-ol-0-0-11345]). The frequency and duration of exercise performed were recorded during the hospitalization. After discharge, patients in the CR group were instructed to continue the exercises by themselves during the observation period.

According to the guidelines of American College of Sports Medicine ([@b26-ol-0-0-11345]), the exercise consisted of the following 4 types of training (median 2.5 metabolic equivalents/20--40 min/day): 1) stretching, 2) strength training, 3) balance training, and 4) endurance training ([@b16-ol-0-0-11345],[@b17-ol-0-0-11345]). A static stretching was conducted for 3--5 min, targeting the quadriceps femoris muscles, hamstrings, hip adductor muscles, and gastrocnemius. The static stretch was held to each muscle for 10--20 seconds at the point of feeling tightness ([@b16-ol-0-0-11345],[@b25-ol-0-0-11345]). Strength training was conducted for 10 min, targeting the quadriceps femoris muscles, gastrocnemius, and tibialis anterior muscles. Quadriceps femoris muscle and iliopsoas strength training were conducted at moderate to high intensity by a hand-held dynamometer. Gastrocnemius and tibialis anterior muscles were conducted trained by the patient\'s weight. One set contained of 10 repetitions, and a maximum of 3 sets were performed ([@b16-ol-0-0-11345],[@b25-ol-0-0-11345]). Balance training contain the patients practicing a one-leg stance and tandem stance for 5--10 min. The patient stood on a straight line and maintain posture in tandem stance training ([@b16-ol-0-0-11345],[@b25-ol-0-0-11345]). Endurance training contained either ergometer or walking for 10--15 min. The intensity of endurance training was 11--13 points on the Borg scale, and the target heart rate was set by using the Karvonen Formula ([@b16-ol-0-0-11345],[@b25-ol-0-0-11345]).

### Diagnosis, the Barcelona Clinic Liver Cancer (BCLC) staging system, tumor node metastasis (TNM) staging, and treatment of HCC

HCC was diagnosed by a combination of tests for serum tumor makers, such as alpha-fetoprotein and des-γ-carboxy prothrombin, and imaging procedures, such as ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), and angiography, or a tumor biopsy ([@b27-ol-0-0-11345]). We evaluated the clinical stage of HCC using the Barcelona Clinic Liver Cancer (BCLC) staging system ([@b27-ol-0-0-11345]) and TNM staging based on the Liver Cancer Study Group of Japan criteria ([@b28-ol-0-0-11345]). We treated the patients according to clinical practice guidelines for HCC of The Japan Society of Hepatology ([@b29-ol-0-0-11345]).

### Additional treatment for recurrence of HCC after initial TACE

When HCC recurred, additional treatment for HCC was selected based on The Japan Society of Hepatology Consensus-Based Treatment Algorithm for HCC ([@b28-ol-0-0-11345]). Moreover, additional HCC treatment with hepatic arterial infusion chemotherapy/tyrosine kinase inhibitors was selected when HCC showed TACE failure/refractoriness defined by any of following criteria: i) an ineffective response after two or more consecutive TACE procedures that is evident on response evaluation CT or MRI after 1--3 months, even after chemotherapeutic agents are changed and/or the feeding artery is reanalyzed; ii) two or more consecutive progressions in the liver (including an increase in the number of tumors compared to that before the previous TACE procedure), even after changing the chemotherapeutic agents and/or reanalysis of feeding artery, on response evaluation CT/MRI after 1--3 months following adequately performed selective TACE; iii) continuous elevation of tumor markers right after TACE even though transient minor reduction is observed; iv) appearance of vascular invasion, or v) appearance of extrahepatic spread ([@b28-ol-0-0-11345]).

### Measurement of skeletal muscle index (SMI) and visceral fat area (VFA)

SMI and VFA were evaluated using CT images obtained before and after TACE. The first CT images were obtained to evaluate HCC before TACE. The second CT images were obtained to evaluate the effectiveness of TACE against HCC. VFA was measure at slices at the umbilical level ([@b29-ol-0-0-11345]). We measured skeletal muscle mass and VFA by using manual tracings on CT images, and their sum was calculated using Image-J software (National Institutes of Health, Bethesda, MD, USA) ([@b30-ol-0-0-11345]). Skeletal muscle mass was normalized by the square of the height, and the data was expressed as SMI.

### Measurement of physical function

Grip strength, 10-meter walking speed, and 6-min walking test were evaluated by qualified physical therapists. Handgrip was measured on the non-dominant hand using a dynamometer (TKK5401; Takei Scientific Instruments Co., Ltd.) according to Japan Society of Hepatology guidelines ([@b7-ol-0-0-11345]). The 10-meter walking speed was measured to evaluate gait speed. To evaluate the 10-meter maximal gait time, 2 meters were added to allow for acceleration before and deceleration after the 10-meter gait test, respectively ([@b31-ol-0-0-11345]). The 6-min walking test was measured by evaluating the total ambulated distance according to the American Thoracic Society guidelines ([@b32-ol-0-0-11345]).

### Biochemical tests

We measured following blood biochemical tests; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, albumin, total bilirubin, creatinine, estimated glomerular filtration rate, creatine kinase, hemoglobin A1c, prothrombin activity, and platelet count. We also measured serum levels of α-fetoprotein, des-γ-carboxy prothrombin.

### Changes in variables before and after TACE

Changes in SMI and VFA between pre- and post-TACE were evaluated by the ΔSMI, and ΔVFA. In addition, ΔSMI and ΔVFA were evaluated by a stratification analysis according to sex. Similarly, changes in each physical function were evaluated by the Δ variables. All Δvariables were evaluated by change in the variable (Δ variable = variable after TACE-variable before TACE).

### Definition of event and follow-up

An event was defined as death from any cause in this study. After discharge, patients were followed up until death or the study censor date by routine physical examinations, biochemical tests, and ultrasonography, CT, or magnetic resonance imaging according to the HCC guidelines of the Japan Society of Hepatology ([@b29-ol-0-0-11345]). The median observation period was 511 days (range, 13--1180 days).

### Statistical analysis

Data are expressed as the median (interquartile range \[IQR\]), range, or number. The differences between the control and CR groups were analyzed by using Wilcoxon rank sum tests. The difference ΔSMI in CR group among the etiologies of liver disease (multiple groups) was examined by analysis of variance followed by Scheffe\'s post hoc test. The difference ΔSMI between female and male or Child-Pugh class A and B/C were analyzed by using Wilcoxon rank sum tests. The level of statistical significance was set at P\<0.05.

A multivariate Cox regression analysis with a stepwise variable selection was used to identify independent variables associated with the prognosis of patients with HCC. In the present study, we did not conduct a univariate analysis, and the explanatory variables were selected in a stepwise manner, minimizing the Bayesian information criterion as previously described ([@b33-ol-0-0-11345]). Overall survival analysis was performed using the Kaplan-Meier method followed by the log-rank test.

Propensity scores for all the patients were estimated by a logistic regression model using the following baseline characteristics as covariates: Age, sex, BCLC stage, Child-Pugh score, and BCAA supplementation as previously described ([@b2-ol-0-0-11345]). To generate 88 pairs of patients, we employed a one-to-one nearest-neighbor matching algorithm with an optimal caliper of 0.2 without replacement. The c-statistic in this study was 0.603, and 88 CLD patients with HCC (control \[n=44\] and CR \[n=44\]) were analyzed.

All the statistical analyses were performed using JMP^®^13 software (SAS Institute Inc.) or the R software package (R Foundation for Statistical Computing, 2012).

Results
=======

### Patient characteristics

Patient characteristics data were obtained before TACE. The characteristics, the CR and control group are shown in [Table I](#tI-ol-0-0-11345){ref-type="table"}. Patients in the CR group were significantly older than those in the control group. The VFA in the CR group was significantly higher than that in the control group. However, there was no significant difference in the female-to-male ratio, body mass index, or SMI between the CR and control groups. No significant difference was seen in TNM stage, BCLC classification, or levels of α-fetoprotein and des-γ-carboxy prothrombin. There was no significant difference in Child-Pugh classification, hemoglobin A1c value, or estimated glomerular filtration rate between the CR and control groups ([Table I](#tI-ol-0-0-11345){ref-type="table"}).

No significant difference was observed between the CR and control groups regarding the prevalence of patients treated with BCAA supplementation, hospitalization period, or the evaluation interval for CT ([Table I](#tI-ol-0-0-11345){ref-type="table"}). There was no significant difference in the number of TACE sessions at the baseline, number of TACE sessions during the observation period, or additional HCC treatment with hepatic arterial infusion of chemotherapy/tyrosine kinase inhibitors during the observation period ([Table I](#tI-ol-0-0-11345){ref-type="table"}). There were no patients who underwent liver transplants during the observation periods.

During the hospitalization, the median length of therapeutic exercise was 6.5 days (IQR, 5--9 days; range, 2--26 days) in the CR group with a median of 3.33 h of exercise performed (IQR, 2.67--4.42 h; range, 1--8.67 h).

### Changes in SMI and VFA

We evaluated changes in SMI by the difference in SMI between before and after TACE. After treatment with TACE, ΔSMI was significantly higher in the CR group than in the control group. There was no significant difference between the CR and control groups regarding the ΔSMI in male patients. On the other hand, there was a significant difference between the CR and control groups regarding ΔSMI in female patients ([Fig. 1](#f1-ol-0-0-11345){ref-type="fig"}). The ΔSMI had no significant association with the etiology of liver disease in the CR group ([Fig. S1](#SD1-ol-0-0-11345){ref-type="supplementary-material"}). Moreover, in the CR group, ΔSMI was not significantly different between male and female patients or between patients classified as Child-Pugh class A and Child-Pugh class B/C ([Fig. S1B and C](#SD1-ol-0-0-11345){ref-type="supplementary-material"}). There was no significant difference in the ΔVFA between the CR and control groups. Moreover, there was no significant difference in VFA between the CR and control groups in both male and female patients ([Fig. 1](#f1-ol-0-0-11345){ref-type="fig"}).

### Correlations between survival period and Δ each variable

Correlations between survival period and the alterations in body composition and physical performance were evaluated using pairwise correlations. There was no significant correlation between the survival period and ΔSMI or ΔVFA ([Table II](#tII-ol-0-0-11345){ref-type="table"}). Moreover, no significant correlation was seen between the survival period and Δ grip strength, Δ10 meter walking speed, or Δ6-min walking test ([Table II](#tII-ol-0-0-11345){ref-type="table"}).

### Associations between survival period and changes in SMI, and baseline SMI, VFA, and serum levels of LDH and total protein

We performed stratification analysis according the changes in SMI. There was no significant difference in survival rate between the patients with increased and decreased SMI in all patients (median 526 vs. 459 days, P=0.6206; [Fig. 2](#f2-ol-0-0-11345){ref-type="fig"}). The impact of changes in SMI on survival was also examined in the CR and control groups. No significant difference was seen in survival between the patients with increased SMI and decreased SMI in both the CR and control groups (CR group; increased SMI vs. decreased SMI; median 541 vs. 569 days, P=0.3856; control group: Increased SMI vs. decreased SMI, median 379 vs. 432 days, P=0.5201; [Figs. S2A and B](#SD1-ol-0-0-11345){ref-type="supplementary-material"}). We also performed stratified analysis for survival according to the several baseline clinical parameters. There was no significant difference in survival rate between the High and Low SMI groups (P=0.7064) and between the High and Low VFA groups (P=0.7530). There was no significant difference in the survival rate between the High and Low LDH groups (P=0.1095). There was no significant difference in the survival rate between the High and Low total protein groups (P=1.0330).

### Independent factors associated with survival

We evaluated the independent factors associated with survival using Cox regression analysis. There was significant difference in serum level of LDH and total protein between the CR and control groups in univariate analysis. However, these factors were not identified as an independent factor for survival in the Cox regression analysis. The CR group and Child-Pugh class A were identified as independent positive factors associated with survival ([Table III](#tIII-ol-0-0-11345){ref-type="table"}). Although BCLC stage was not significantly associated with survival, the number of TACE sessions at baseline were an independent negative factor for survival ([Table III](#tIII-ol-0-0-11345){ref-type="table"}). The number of TACE sessions during the observation period and additional HCC treatment with hepatic arterial infusion of chemotherapy/tyrosine kinase inhibitors during the observation period were not selected by a stepwise procedure.

We also evaluated independent factors associated with survival in the CR and control groups respectively. In the CR group, the number of TACE sessions during the observation and Child-Pugh class were identified as independent factors for survival (P=0.0004 and P=0.0278). In the Control group, BCLC stage was identified as an independent factor for the survival (P=0.0034).

### Impact of CR on survival period

Kaplan-Meier analysis was used to compare the survival rate between the CR and control groups. The median observation period was 511 days (range, 13--1180 days). The survival rate of the CR group was significantly higher than that of the control group on Kaplan-Meier analysis (median 552 vs. 424 days, P=0.0359; [Fig. 3A](#f3-ol-0-0-11345){ref-type="fig"}).

### Impact of CR on survival period after propensity score matching

After propensity score matching, we evaluated overall survival by Kaplan-Meier analysis. Propensity scores for all the patients were estimated using the following baseline characteristics as covariates: Age, sex, BCLC stage, Child-Pugh score, and BCAA supplementation. There was no significant difference in observation period between the CR and control groups ([Table IV](#tIV-ol-0-0-11345){ref-type="table"}). No significant difference was seen in number of TACE session at baseline and SMI between the two groups ([Table IV](#tIV-ol-0-0-11345){ref-type="table"}). The survival rate of the CR group was significantly higher than that of the control group (median 529 vs. 369 days, P=0.0332; [Fig. 3B](#f3-ol-0-0-11345){ref-type="fig"}).

Discussion
==========

In this study, we investigated effects of CR on the prognosis of patients with HCC who underwent TACE. The survival rate was higher in HCC patients with CR than in HCC patients without CR. Cox regression analysis demonstrated that CR was an independent factor for survival. These results may indicate that CR has beneficial effect on prognosis of patients with HCC who underwent TACE.

In the present study, SMI significantly increased in the CR group without worsening liver function in patients with CLD and HCC who underwent TACE. Dawson *et al* ([@b34-ol-0-0-11345]) showed that CR improves muscle mass in patients with prostate cancer during androgen treatment. We also reported previously that CR increased muscle mass in patients with HCC during treatment ([@b14-ol-0-0-11345]). Taken together, CR may improve the muscle mass of patients with cancer in spite of treatment for cancer.

In the female, but not in the male, ΔSMI in the CR group was significantly higher than that in the control group. This gender difference could be accounted for a marked decrease of ΔSMI in female of the control group. In our previous study, skeletal muscle mass was also significantly decreased in female than in male HCC patients who underwent TACE ([@b35-ol-0-0-11345]). A possible reason for the gender difference is sex hormones. Testosterone has potent anabolic effects on skeletal muscle, leading to muscle protein synthesis and subsequently increases muscle mass ([@b36-ol-0-0-11345]). Women have low serum testosterone levels and serum free testosterone levels are reported to be positively correlated with skeletal muscle mass in women ([@b37-ol-0-0-11345]).

The prognosis of solid malignancies is widely known to be dependent on the cancer stage, such as the TNM system ([@b38-ol-0-0-11345]). In this study, BCLC stage was not identified as an independent factor associated with survival. It remains unclear why the stage of HCC was not a risk factor for survival. However, all enrolled patients with HCC were treated with TACE, and patients with BCLC stage B accounted for approximately 80% of enrolled patients. Therefore, the narrow distribution of HCC stage may be a possible reason that HCC stage was not a risk factor for the prognosis of HCC patients treated with TACE.

Loss of muscle mass is an independent prognostic factor for patients with HCC ([@b11-ol-0-0-11345]). Therefore, an increase in skeletal muscle mass is thought to be related to the improvement of the prognosis of patients with HCC. We investigated the impact of the change in SMI on survival in patients with HCC; however, an increase in SMI was not identified as an independent prognostic factor in patients with HCC. In addition, there was no significant difference in survival rate between patients with increased SMI and patients with decreased SMI in all patients or in the CR group. Although CR is reported to improve the prognosis of patients with cancer ([@b39-ol-0-0-11345]), our study indicates that CR may improve the prognosis regardless of changes in muscle mass in patients with HCC.

In this study, we first showed that maintaining physical activity by CR is more important than increasing muscle mass to improve the prognosis of patients with HCC. The beneficial effect of CR was also observed after propensity score matching. Although it remains unclear why CR improved the prognosis, exercise is reported to exert several beneficial effects against cancer.

First, exercise may suppress the development and proliferation of HCC through modulation of insulin-like growth factor 1 signal. Insulin-like growth factor 1 concentration is related to an increase in tumor growth and development of colon cancer in *in vivo* and *in vitro* studies ([@b40-ol-0-0-11345]). Exercise improves insulin resistance and decreases levels of insulin-like growth factor 1 in patients with breast cancer ([@b39-ol-0-0-11345]). Moreover, exercise is also known to enhance the expression of p21, insulin-like growth factor-binding protein-3, and PTEN, which suppress insulin-like growth factor 1 signaling in a cancer mouse model ([@b41-ol-0-0-11345]).

Second, exercise may suppress HCC growth through suppression of the Warburg effect. Aerobic exercise is reported to exert an anti-Warburg effect, leading to an increase in lactate clearance capacity in animal and human studies ([@b42-ol-0-0-11345]). Lactate is an important metabolic compound involved and necessary in all main sequela for carcinogenesis, specifically: Angiogenesis, immune escape, cell migration, metastasis, and self-sufficient metabolism ([@b42-ol-0-0-11345]). Lactate metabolism is directly correlated with the prognosis of patients with cancer ([@b43-ol-0-0-11345]). Thus, exercise-induced alteration in lactate metabolism may suppress HCC growth.

Besides the above mechanisms, myokines are known to suppress cancer cells directly and indirectly ([@b44-ol-0-0-11345]). Contracting muscle fibers release myokines including interleukin, oncostatin, and secreted protein acidic and rich in cysteine ([@b44-ol-0-0-11345]). Interleukin is reported to increase mobilization of natural killer lymphocytes and to reduce the growth rate of liver cancer in an *in vivo* study ([@b45-ol-0-0-11345]). Oncostatin M was reported to have an anti-proliferative and apoptotic effect on breast-cancer cells in an *in vivo* study ([@b46-ol-0-0-11345]). Secreted protein acidic and rich in cysteine is known to be associated with apoptosis of colon cancer cells in mice and humans ([@b47-ol-0-0-11345]). Thus, a possible hypothesis is that CR may inhibit progression of HCC through up-regulation of myokines, leading to improvement in the prognosis.

There were limitations in this study. This was not a randomized controlled trial with constant duration of CR and irregular time intervals between the first and second CT. Patients who did not agree to exercise were defined as the control group. In addition, the exclusion criteria for the CR group would be associated with death. Thus, patients in the control group might be more deconditioned than patients in the CR group. Second, we did not evaluate the physical activity of patients before TACE and after discharge. Continuous execution of CR should have been evaluated at outpatient visits. Third, changes in eating habits were not evaluated in this study. Since exercise is known to affect eating habits ([@b48-ol-0-0-11345]) and, changes in eating habits might be a confounding factor of CR. Fourth, there were no patients who underwent liver transplantation during the observation period, suggesting the selection bias. Fifth, we did not evaluate any immune-related variable, although exercise is known to activate immunity and may suppress proliferation of cancer cells through modulation of regulation of the tumor microenvironment ([@b49-ol-0-0-11345],[@b50-ol-0-0-11345]). Thus, multicenter randomized controlled trials should be conducted with constant duration of CR and regular interval of CT examinations, evaluation of physical activity and eating habits before and after TACE, and various treatments for HCC after TACE, including liver transplantation. In addition, effects of CR on immune-related variable should be evaluated to elucidate the mechanisms for CR-related improvement of prognosis in patients with HCC.

In conclusion, we showed that CR not only increased muscle mass but also prolonged survival in patients with HCC who underwent TACE. Moreover, CR, but not an increase in muscle mass, was an independent factor for survival. Thus, exercise may exert beneficial effects on the prognosis independent from muscle hypertrophy in patients with HCC. Patients with HCC are recommended to maintain physical activity rather than be on bed rest even after a diagnosis of HCC.
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BCAA

:   branched-chain amino acid

CLD

:   chronic liver disease

CR

:   cancer rehabilitation

CT

:   computed tomography
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:   hepatocellular carcinoma
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:   visceral fat area
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\(A\) Difference in survival rate between the CR and control groups. (B) Difference in survival rate between the CR and control groups after propensity score matching. CR, cancer rehabilitation.
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Patient characteristics.

                                                                                                Control group                                Cancer rehabilitation group                                                                       
  ------------------------------------------------------------------------------- ------------- -------------------------------------------- ----------------------------- -------------------------------------------------- ---------------- --------
  Observation period                                                              N/A           424 (233--734)                               13--1180                      522 (345.5--835)                                   56-1038.2        0.0299
  Number, n                                                                       N/A           67                                                                         85                                                                  
  Age, years                                                                      N/A           74.0 (68.0--78.0)                            41.0--85.0                    75.0 (71.0--80.0)                                  63.0--91.0       0.0371
  Sex, female/male                                                                N/A           30%/70% (20/47)                              N/A                           40%/60% (34/51)                                    N/A              0.1943
  Body mass index, kg/m^2^                                                        18.5--24.9    22.3 (20.4--23.9)                            16.0--32.7                    23.0 (21.0--25.7)                                  16.7--37.8       0.0597
  Etiology of liver disease, AIH/ Alcohol/HBV/HCV/NASH/others                     N/A           0%/11.9%/6%/76.1%/4.5%/1.5% (0/8/4/51/3/1)   N/A                           3.5%/10.6%/9.4%/63.5%/1.2%/11.8% (3/11/8/54/1/8)   N/A              0.0901
  Viremia of HCV, presence/absence                                                N/A           44/7                                         N/A                           41/13                                              N/A              0.1771
  HCC stage, I/II/III/IV                                                          N/A           4.5%/23.9%/44.8%/26.8% (3/16/30/18)          N/A                           10.6%/38.8%/31.8%/18.8% (9/33/27/16)               N/A              0.0675
  BCLC classification, stage A/B/C                                                N/A           4.5%/82.1%/13.4% (3/55/9)                    N/A                           10.6%/75.3%/14.1% (9/64/12)                        N/A              0.3668
  Number of TACE sessions at baseline                                             N/A           1 (0--2)                                     0--9                          1 (0--2)                                           0--8             0.5497
  Number of TACE sessions during the observation period                           N/A           3 (1--5)                                     1--12                         3 (1--4)                                           1--9             0.2033
  Additional HCC treatment with HAIC/TKIs during the observation period, Yes/No   N/A           32.8%/67.2% (22/45)                          N/A                           32.9%/67.1% (28/57)                                N/A              0.9890
  AFP, ng/ml                                                                      ≤10.0         50.9 (11.4--348.5)                           1.3--22385.0                  36.2 (6.9--229.1)                                  1.3--67036.0     0.2632
  DCP, mAU/ml                                                                     ≤40.0         257.0 (44.5--4523.5)                         10.0--745283.0                101.0 (33.5--777.5)                                12.0--104513.0   0.1692
  Child-Pugh class, A/B/C                                                         N/A           52.2%/47.8% /0% (35/32/0)                    N/A                           62.4%/37.7% /0% (53/32/0)                          N/A              0.2099
  AST, IU/l                                                                       13--30        48(32--68)                                   13--177                       43 (30.5--54)                                      18--183          0.0804
  ALT, IU/l                                                                       10--30        35 (23--55)                                  7--101                        29 (22--39.5)                                      7--186           0.1518
  Lactate dehydrogenase, IU/l                                                     120--240      238 (201--277)                               118--498                      211 (181--251.5)                                   129--624         0.0215
  ALP, IU/l                                                                       115--359      381 (291--522)                               144--1170                     351 (288--500)                                     180--1467        0.5330
  GGT, IU/l                                                                       13--64        47 (28.75--96.25)                            17--395                       44 (25.5--75.5)                                    9--551           0.3759
  Cholinesterase, U/l                                                             201--421      130 (93.5--174.75)                           47--314                       155 (117--200)                                     53--360          0.0723
  Total protein, g/dl                                                             6.6--8.1      7.21 (6.94--7.59)                            5.65--8.52                    7.16 (6.66--7.62)                                  5.86--8.89       0.5160
  Albumin, g/dl                                                                   4.1--5.1      3.33 (2.97--3.63)                            2.31--4.40                    3.37 (3.05--3.71)                                  2.27--4.39       0.4058
  Total bilirubin, mg/dl                                                          0.40--1.20    0.99 (0.76--1.27)                            0.33--2.31                    0.82 (0.64--1.22)                                  0.31--2.78       0.0764
  BUN, mg/dl                                                                      8.6--22.9     16.1 (13.2--20.8)                            8.8--36.9                     16.9 (14--19.75)                                   5.9--47.6        0.9084
  Creatinine, mg/dl                                                               0.65--1.07    0.74 (0.60--0.95)                            0.35--8.50                    0.73 (0.61--0.91)                                  0.43--1.91       0.5513
  eGFR, ml/min/1.73 m^2^                                                          \>90.0        74.5 (55--92.2)                              5.5--129.5                    71.7 (55.8--86.8)                                  27.3--119.5      0.5330
  Total cholesterol, mg/dl                                                        150--199      146 (127--172.5)                             81--254                       136 (125--153)                                     79--233          0.1781
  Creatine kinase, U/l                                                            59--248       100.5 (67.5--169.3)                          34--386                       87 (55--127.25)                                    10--374          0.0611
  HbA1c, %                                                                        4.3--5.8      5.8 (5.2--6.35)                              4.6--8.0                      5.8 (5.5--6.4)                                     4.3--13.4        0.4915
  Prothrombin activity, %                                                         80--120       74.5 (63--88.75)                             14.6--118                     79(67.5--89.5)                                     14.5--117        0.5247
  Red blood cell count, ×10^4^/µl                                                 435--555      377 (341--411)                               186--498                      389 (352--420)                                     249--615         0.1877
  Hemoglobin, g/dl                                                                13.7--16.8    11.7 (10.2--12.8)                            7.0--16.4                     11.7 (10.45--12.75)                                7.3--15.6        0.7807
  White blood cell count, /µl                                                     3,300-8,600   3,500 (2,700--4,700)                         1700--9700                    3,800 (3,150--5,150)                               1,800-21,100     0.1808
  Platelet count, ×10^3^/mm^3^                                                    15.8--34.8    9 (6.9--14.5)                                3.4--24.4                     10.8 (8.4--13.95)                                  3.2--46.6        0.1809
  BCAA supplementation, yes/no                                                    N/A           67.2%/32.8% 45/22                            N/A                           61.1%/38.8% 52/33                                  N/A              0.4456
  Hospitalization, days                                                           N/A           15 (13--20)                                  8--38                         15 (11--21)                                        7--55            0.4862
  Evaluation period for CT, days                                                  N/A           53 (34--84)                                  7--309                        50 (35--80)                                        7--312           0.8324
  Period between TACE and CT, days                                                N/A           11 (9--15)                                   6--26                         9 (7--20)                                          2--125           0.3958
  Exercise days during hospitalization, days                                      N/A           N/A                                          N/A                           6.5 (5--9)                                         2--26            N/A
  Total duration of exercise, h                                                   N/A           N/A                                          N/A                           3.3 (2.7--4.4)                                     1-8.7            N/A
  Metabolic equivalents                                                           N/A           N/A                                          N/A                           2.5 (2--3)                                         2--4             N/A
  Grip strength, kg                                                               N/A           N/A                                          N/A                           24.1 (19.2--28.9)                                  10.8--42.8       N/A
  10-meter walk test, sec                                                         N/A           N/A                                          N/A                           7.33 (6.10--9.81)                                  5.41--13.55      N/A
  6-min walk test, meter                                                          N/A           N/A                                          N/A                           379.81 (288.85--421.52)                            26.2--574.1      N/A
  SMI, cm^2^/m^2^                                                                 N/A           31.5 (22.4--39.1)                            13.8--57.0                    29.7 (23.7--34.6)                                  11.9--51.2       0.3632
  VFA, cm^2^/m^2^                                                                 N/A           19.23 (10.10--30.96)                         2.13--71.95                   26.55(15.75--36.41)                                2.13--92.65      0.012

Data are expressed the as median (IQR), range, or number. N/A, not applicable; SMI, skeletal muscle index; AIH, autoimmune hepatitis; HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, non-alcoholic steatohepatitis; BCLC, Barcelona Clinic Liver Cancer; TACE, transcatheter arterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; TKIs, tyrosine kinase inhibitors; AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; BCAA, branched-chain amino acids; CT, computed tomography; SMI, skeletal muscle mass index; VFA, visceral fat area; IQR, interquartile range.

###### 

Pairwise correlations between survival period and Δeach variable.

  Variables             Correlation coefficient   P-value
  --------------------- ------------------------- ---------
  ΔSMI                  −0.00029                  0.9971
  ΔVFA                  −0.03869                  0.6338
  Δgrip strength        −0.09365                  0.4767
  Δ10 m walking speed   −0.04024                  0.9121
  Δ6-min walk test      −0.19864                  0.1712

SMI, skeletal muscle mass index; VFA, visceral fat area.

###### 

Independent factor for survival.

  Factors                              Estimate   95% Confidence interval   P-value
  ------------------------------------ ---------- ------------------------- ---------
  Group (CR)                           1.760      0.914--3.226              0.0010
  Child-Pugh (class A-B)               1.602      0.426--2.998              0.0129
  Number of TACE session at baseline   −0.843     −1.465--0.337             0.003

N/A, not applicable; CR, cancer rehabilitation; TACE, transcatheter arterial chemoembolization.

###### 

Patient characteristics after propensity score matching.

                                                                                               Control group                    Cancer rehabilitation group                                                       
  ------------------------------------------------------------------------------ ------------- -------------------------------- ----------------------------- ---------------------------------- ---------------- --------
  Observation period                                                             N/A           369 (215--659.8)                 13--1114                      529 (256.5--862)                   56--1131         0.0513
  Number, n                                                                      N/A           44                                                             44                                                  
  Age, years                                                                     N/A           74.5 (69.25--78.0)               59.0--84.0                    73.5 (70.0--77.75)                 63.0--88.0       1.0000
  Sex, female/male                                                               N/A           31.8%/68.2% (14/30)              N/A                           29.6%/70.5% (13/31)                N/A              0.8172
  Body mass index, kg/m^2^                                                       18.5--24.9    22.6 (20.1--24.2)                16.0--32.7                    22.9 (20.9--25.9)                  17.8--30.5       0.3877
  Etiology of liver disease, AIH/                                                N/A           0%/9%/4.6%/77.3%/                N/A                           2.3%/15.9%/11.4%/56.8%/            N/A              0.2052
  Alcohol/HBV/HCV/NASH/others                                                                  6.8%/2.3% (0/4/2/34/3/1)                                       2.3%/11.3% (1/7/5/25/1/5)                           
  HCV viremia, presence/absence                                                  N/A           30/4                             N/A                           20/5                               N/A              0.3846
  HCC stage, I/II/III/IV                                                         N/A           4.6%/25%/50%/20.5% (2/11/22/9)   N/A                           0%/45.5%/36.4%/18.2% (0/20/16/8)   N/A              0.1317
  BCLC classification, stage A/B/C                                               N/A           4.6%/81.8%/13.6% (3/36/6)        N/A                           0%/84.1%/15.9% (0/37/7)            N/A              0.3516
  Number of TACE session at baseline                                             N/A           1(0--2.75)                       0--9                          1(1--3)                            0--5             0.5514
  Number of TACE session during the observation period                           N/A           3 (1--5)                         1--12                         4 (2--5)                           1--7             0.1359
  Additional HCC treatment with HAIC/TKI during the observation period, yes/no   N/A           15.9%/84.1% (7/37)               N/A                           25.0%/75.0% (11/33)                N/A              0.2905
  AFP, ng/ml                                                                     ≤10.0         58.35 (13.58--391.5)             1.3--22385.0                  57.9 (7.01--229.3)                 2.2 −67036.0     0.6403
  DCP, mAU/ml                                                                    ≤40.0         153.0 (36.0--1293.0)             10.0--71031.0                 159.5 (36.25--2908.25)             16.0--104513.0   0.6589
  Child-Pugh class, A/B/C)                                                       N/A           52.3%/47.7% /0% (23/21/0)        N/A                           54.6%/45.5% /0% (24/20/0)          N/A              0.8308
  AST, IU/l                                                                      13--30        49.5 (32--74)                    14--177                       43 (32.3--57)                      22--113          0.1803
  ALT, IU/l                                                                      10--30        38 (23.3--60)                    7--101                        29 (23--44.5)                      7--114           0.2000
  Lactate dehydrogenase, IU/l                                                    120--240      234.5 (197.5--274)               118--498                      212 (180.3--258.5)                 138--624         0.1341
  ALP, IU/l                                                                      115--359      373 (284.8--511.8)               144--1170                     325 (291--467)                     214--1467        0.8315
  GGT, IU/l                                                                      13--64        44.5 (29.3--72.8)                17--395                       54.5 (27.5--83.5)                  12--551          0.5204
  Cholinesterase, U/l                                                            201--421      128 (87.3--175.3)                47--314                       157 (103--194)                     57--360          0.1829
  Total protein, g/dl                                                            6.6--8.1      7.28 (6.95--7.58)                6.32--8.2                     6.9 (6.54--7.49)                   6.04--8.89       0.0389
  Albumin, g/dl                                                                  4.1--5.1      3.36 (2.99--3.63)                2.43--4.40                    3.37 (2.99--3.70)                  2.27--4.39       0.6856
  Total bilirubin, mg/dl                                                         0.40--1.20    0.99 (0.76--1.28)                0.39--2.03                    0.91 (0.68--1.27)                  0.31--2.78       0.5017
  BUN, mg/dl                                                                     8.6--22.9     16.1 (11.7--21.3)                8.8--31.2                     17.0 (14.5--19.6)                  5.9--47.6        0.7480
  Creatinine, mg/dl                                                              0.65--1.07    0.74 (0.60--0.95)                0.35--8.50                    0.74 (0.61--0.94)                  0.43--1.91       0.9368
  eGFR, ml/min/1.73 m^2^                                                         \>90.0        71.2 (55.5--94.1)                5.5--129.5                    72.7 (57.2--90.4)                  27.3--108.4      0.9800
  Total cholesterol, mg/dl                                                       150--199      141(124--171.8)                  81--235                       138 (125.8--150)                   79--233          0.6162
  Creatine kinase, U/l                                                           59--248       120.5 (72.3--169.0)              34.0--386.0                   89 (58.8--141.0)                   10--297          0.2235
  HbA1c, %                                                                       4.3--5.8      5.9 (5.3--6.5)                   4.7--8.0                      5.7 (5.3--6.6)                     4.3--13.4        0.9609
  Prothrombin activity, %                                                        80--120       78.0 (67.5--94.0)                14.6--118                     76.0 (65.3--85.5)                  14.5--117        0.5787
  Red blood cell count, ×10^4^/µl                                                435--555      377 (353--407.8)                 312--466                      389 (345.3--426.8)                 249--615         0.5990
  Hemoglobin, g/dl                                                               13.7--16.8    11.7 (10.53--12.8)               7.3--15.2                     11.5 (10.1--12.95)                 7.3--15.6        0.8444
  White blood cell count, /µl                                                    3,300-8,600   3,500 (2,700--4175)              1,700-9,700                   3,800 (3,025--5,300)               1,800-21,100     0.2104
  Platelet count, ×10^3^/mm^3^                                                   15.8--34.8    8.6 (6.9--14.4)                  4.7--24.4                     10.8 (8.5--14.6)                   3.6--46.6        0.1873
  BCAA supplementation, yes/no                                                   N/A           70.4%/29.6%31/13                 N/A                           63.6%/36.4%28/16                   N/A              0.4963
  Hospitalization, days                                                          N/A           14.5 (13--21)                    9--35                         15.5 (11--22.8)                    10--43           0.9099
  Evaluation period for CT, days                                                 N/A           48.5 (31.5--77.5)                7--309                        58.5 (41.8--80.8)                  23--312          0.1789
  Period between TACE and CT, days                                               N/A           10 (9--14)                       6--26                         10 (8.3--28.8)                     6--125           0.4373
  Exercise days during hospitalization, days                                     N/A           N/A                              N/A                           7.0 (5--9.3)                       2--20            N/A
  Total times of exercise, h                                                     N/A           N/A                              N/A                           3.3 (2.7--4.4)                     1.3--8.3         N/A
  Metabolic equivalents                                                          N/A           N/A                              N/A                           2.5 (2--3)                         2--4             N/A
  Grip strength, kg                                                              N/A           N/A                              N/A                           23.8 (19.2--30.4)                  9.1--42.8        N/A
  10-meter walk test, sec                                                        N/A           N/A                              N/A                           7.88 (6.96--12.17)                 6.69--13.55      N/A
  6-min walk test, meter                                                         N/A           N/A                              N/A                           359.9 (302.3--420.0)               26.2--574.1      N/A
  SMI, cm^2^/m^2^                                                                N/A           30.5 (22.4--38.7)                13.8--48.3                    31.4 (27.0--34.6)                  20.0--46.4       0.7417
  VFA, cm^2^/m^2^                                                                N/A           53.23 (30.85- 85.24)             5.00--193.06                  53.02(37.22--95.86)                4.37--240.75     0.6078

Data are expressed as the median (IQR), range or number. IQR, interquartile range; N/A, not applicable; SMI, skeletal muscle index; AIH, autoimmune hepatitis; HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, non-alcoholic steatohepatitis; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; TACE, transcatheter arterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; TKIs, tyrosine kinase inhibitors; AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; BCAA, branched-chain amino acids; CT, computed tomography; SMI, skeletal muscle mass index; VFA, visceral fat area.
